Large Pharma Integrates NextDocs eTMF, CTMS and Investigator Portal
NextDocs announced that leading pharmaceutical and biologics companies implemented late last year the NextDocs clinical solution suite
NextDocs announced that leading pharmaceutical and biologics companies implemented late last year the NextDocs clinical solution suite across more than 200 clinical trials to manage regulated content and compliance, and bring together clinical trial constituencies onto a single management system.
The pharma sponsor initially deployed the NextDocs eTMF solution over two years ago to manage clinical trial documents. In 2013, the company expanded the deployment to include Clinical Research Organization (CRO) access. Subsequently, the company deployed the NextDocs Trial Exchange (TrX) investigator portal solution to provide external access to a user community of over 30,000 investigators across more than 10,000 trial sites.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
